Skip to main content
AVECHO BIOTECHNOLOGY LIMITED logo

AVECHO BIOTECHNOLOGY LIMITED — Investor Relations & Filings

Ticker · AVE ISIN · AU0000047441 LEI · 529900FA9G9T82C2LV25 ASX Manufacturing
Open in API
Filings indexed 881 across all filing types
Latest filing 2025-04-29 Interim / Quarterly Rep…
Country AU Australia
Listing ASX AVE

About AVECHO BIOTECHNOLOGY LIMITED

https://avecho.com.au/

Avecho Biotechnology Limited develops and commercializes human and animal health products using its proprietary drug delivery system, Tocopheryl Phosphate Mixture (TPM®). Derived from Vitamin E, TPM® is designed to enhance the solubility and absorption of active ingredients through the skin and digestive tract. The company focuses on applying this technology to pharmaceuticals, nutraceuticals, and animal health sectors. A primary area of development includes medicinal cannabis, where Avecho has produced high-bioavailability cannabidiol (CBD) softgel capsules for therapeutic use. The company’s portfolio also includes applications in pain management and dermatology, leveraging TPM® to improve the delivery of poorly soluble molecules and enhance the efficacy of existing treatments.

Recent filings

Filing Released Lang Actions
March 2025 Quarterly Activities Report & Appendix 4C 8 pages 597.5KB
Interim / Quarterly Report Classification · 95% confidence The document is an ASX announcement dated 30 April 2025 presenting Avecho Biotechnology Limited's Quarterly Activities Report and Appendix 4C for the quarter ended 31 March 2025. It includes detailed operational updates, a licensing agreement, clinical trial progress, manufacturing updates, and a detailed quarterly cash flow report (Appendix 4C) with financial data for the quarter. The presence of substantive financial data and analysis for a quarter shorter than a full fiscal year, along with the quarterly cash flow statement, aligns with the definition of an Interim / Quarterly Report (IR). The document is not merely an announcement of a report but contains the actual report content and financial statements. Therefore, the correct classification is Interim / Quarterly Report (IR). Q1 2025
2025-04-29 English
Notice of Annual General Meeting/Proxy Form 22 pages 1.2MB
AGM Information Classification · 100% confidence The document is a Notice of Annual General Meeting (AGM) for Avecho Biotechnology Limited, detailing the date, time, location, agenda, and resolutions to be considered at the AGM. It includes proxy voting instructions, voting exclusions, and explanatory statements related to the AGM. The document explicitly states it is the Notice of Annual General Meeting and includes the Explanatory Statement and Proxy Form. It does not contain financial statements or detailed financial performance data itself but refers to the Annual Report to be received and considered at the meeting. Therefore, this document is the AGM Information material, not the Annual Report or any other report type.
2025-04-23 English
Section 708A Cleansing Statement 1 page 99.4KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 16 April 2025, titled 'Section 708A Cleansing Notice and Appendix 2A'. It confirms the issuance of fully paid ordinary shares to employees under an equity incentive plan without disclosure under Part 6D.2 of the Corporations Act. The notice references compliance with specific sections of the Corporations Act and states that an Appendix 2A relating to the share issue will be released shortly. The document is short (2471 characters) and primarily serves as a regulatory announcement about a share issue and compliance notice, not a full financial report or detailed filing. It does not contain financial statements or detailed analysis but is a formal regulatory disclosure. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-04-15 English
Application for quotation of securities - AVE 7 pages 21.2KB
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Appendix 2A - Application for quotation of securities' and details the application for quotation of securities issued under an employee incentive scheme by Avecho Biotechnology Limited. It includes specifics such as the number of securities to be quoted, issue date, and mentions compliance with ASX Listing Rules. The content is focused on the application and announcement of new securities to be quoted on the ASX, rather than a financial report or earnings release. This type of document corresponds to announcements related to new share issues or capital changes. Therefore, the appropriate classification is 'Share Issue/Capital Change' (SHA). The document length (6399 characters) and detailed content support this classification with high confidence.
2025-04-15 English
Avecho receives initial US$3M upfront payment from Sandoz 3 pages 205.6KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 28 March 2025, detailing a licensing agreement between Avecho Biotechnology Limited and Sandoz AG for the commercial rights to a CBD product in Australia. It discusses the upfront payment, milestone payments, royalties, and commercial rights but does not contain any financial statements, detailed financial performance data, or comprehensive financial analysis. The document is approximately 11,607 characters long, which is substantial but the content is clearly an announcement of a capital/licensing deal rather than a financial report or earnings release. There is no indication of quarterly or annual financial results, nor is it a transcript or management discussion. The focus is on a financing/licensing update related to the company's commercial activities and capital inflow. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2025-03-27 English
Avecho to present at NWR Virtual Healthcare Conference 2 pages 149.2KB
Investor Presentation Classification · 95% confidence The document is an ASX announcement dated 13 March 2025 from Avecho Biotechnology Limited. It announces the company's upcoming presentation at the NWR Virtual Healthcare Conference, focusing on a major licensing agreement and the significance of their Phase III clinical trial for a cannabidiol product. The text includes details about the presentation logistics, company background, and clinical trial information. There are no financial statements, detailed financial performance data, or comprehensive management discussion typical of annual or interim reports. The document is primarily an announcement of an investor presentation event rather than the presentation itself or a detailed report. Therefore, the most appropriate classification is Investor Presentation (IP). The document length (6495 characters) supports it being a detailed announcement rather than a brief notice or a full report.
2025-03-12 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.